Metagenomi, Inc. Common Stock
MGXNASDAQHealthcare● Active
$1.29
+$0.01(+0.78%)
Market Cap$48564449
P/E Ratio—
52W High$3.95
52W Low$1.24
Metagenomi, Inc. Common Stock (MGX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MGX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$0.61
Est. -$0.60 · -1.7%
Revenue
$0.00B
Est. $0.01B · -78.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
MGX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.03
Rev. $1.54B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.03
Rev. Est.$1.54B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.55 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 11, 2026 | -$0.60 | -$0.61 | -1.7% | $0.00B | $0.01B | -78.9% |
| ▼ Q1 FY2026 | Mar 5, 2026 | -$0.58 | -$0.60 | -3.5% | $0.00B | $0.01B | -46.6% |
| ▲ Q4 FY2025 | Nov 11, 2025 | -$0.60 | -$0.55 | +8.3% | $0.01B | $0.01B | +10.7% |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$0.68 | -$0.54 | +20.6% | $0.01B | $0.01B | +7.2% |
| ▼ Q2 FY2025 | May 13, 2025 | -$0.62 | -$0.68 | -9.7% | $0.00B | $0.01B | -50.3% |
| ▼ Q1 FY2025 | Mar 17, 2025 | -$0.62 | -$0.63 | -1.6% | $0.01B | $0.01B | +4.2% |
| ▲ Q4 FY2024 | Nov 13, 2024 | -$0.70 | -$0.45 | +35.7% | $0.01B | $0.01B | +70.3% |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.55
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Miss
EPS Actual
-$0.61
EPS Est.
-$0.60
EPS Surpr.
-1.7%
Revenue
$0.00B
Q1 FY2026
Mar 5, 2026Miss
EPS Actual
-$0.60
EPS Est.
-$0.58
EPS Surpr.
-3.5%
Revenue
$0.00B
Q4 FY2025
Nov 11, 2025Beat
EPS Actual
-$0.55
EPS Est.
-$0.60
EPS Surpr.
+8.3%
Revenue
$0.01B
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$0.54
EPS Est.
-$0.68
EPS Surpr.
+20.6%
Revenue
$0.01B
Q2 FY2025
May 13, 2025Miss
EPS Actual
-$0.68
EPS Est.
-$0.62
EPS Surpr.
-9.7%
Revenue
$0.00B
Q1 FY2025
Mar 17, 2025Miss
EPS Actual
-$0.63
EPS Est.
-$0.62
EPS Surpr.
-1.6%
Revenue
$0.01B
Q4 FY2024
Nov 13, 2024Beat
EPS Actual
-$0.45
EPS Est.
-$0.70
EPS Surpr.
+35.7%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.67 | $-0.53 | $-0.30 | 1 |
| Q3 FY2027 | $-0.67 | $-0.53 | $-0.30 | 1 |
| Q2 FY2027 | $-0.67 | $-0.53 | $-0.30 | 1 |
| Q1 FY2027 | $-0.65 | $-0.52 | $-0.29 | 1 |
| Q4 FY2026 | $-0.56 | $-0.45 | $-0.25 | 1 |
| Q3 FY2026 | $-0.60 | $-0.57 | $-0.54 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 11, 2026 | -1.7% | $1.41 | $1.35 | -4.26% |
| ▼ Q1 FY2026 | Mar 5, 2026 | -3.5% | $1.60 | $1.61 | +0.63% |
| ▲ Q4 FY2025 | Nov 11, 2025 | +8.3% | $2.15 | $2.20 | +2.33% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +20.6% | $1.83 | $1.88 | +2.73% |
| ▼ Q2 FY2025 | May 13, 2025 | -9.7% | $1.55 | $1.60 | +3.23% |
| ▼ Q1 FY2025 | Mar 17, 2025 | -1.6% | $1.94 | $1.88 | -3.09% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +35.7% | $2.21 | $2.11 | -4.52% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +50.9% | $3.25 | $3.10 | -4.62% |
Q2 FY2026-4.26%
Report Date
May 11, 2026
EPS Beat/Miss
-1.7%
Price Before
$1.41
Price After
$1.35
Q1 FY2026+0.63%
Report Date
Mar 5, 2026
EPS Beat/Miss
-3.5%
Price Before
$1.60
Price After
$1.61
Q4 FY2025+2.33%
Report Date
Nov 11, 2025
EPS Beat/Miss
+8.3%
Price Before
$2.15
Price After
$2.20
Q3 FY2025+2.73%
Report Date
Aug 12, 2025
EPS Beat/Miss
+20.6%
Price Before
$1.83
Price After
$1.88
Q2 FY2025+3.23%
Report Date
May 13, 2025
EPS Beat/Miss
-9.7%
Price Before
$1.55
Price After
$1.60
Q1 FY2025-3.09%
Report Date
Mar 17, 2025
EPS Beat/Miss
-1.6%
Price Before
$1.94
Price After
$1.88
Q4 FY2024-4.52%
Report Date
Nov 13, 2024
EPS Beat/Miss
+35.7%
Price Before
$2.21
Price After
$2.11
Q3 FY2024-4.62%
Report Date
Aug 14, 2024
EPS Beat/Miss
+50.9%
Price Before
$3.25
Price After
$3.10
Avg Beat Reaction-1.02%
Avg Miss Reaction-0.87%
Beat Rate4 / 8 quarters
Largest Move-4.62% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MGX ends December
Metagenomi, Inc. Common Stock (MGX) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-0.61 — missing the analyst consensus of $-0.60 by -1.7%. The next MGX earnings date is expected around September 1, 2026.
Each quarter, investors track MGX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MGX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MGX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MGX earnings · 5 questionsMetagenomi, Inc. Common Stock's next earnings report is expected around September 1, 2026. MGX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MGX historically reports after market close (AMC).
MGX earnings datewhen is MGX earningsMGX next earnings datewhen does MGX report earningsMGX earnings calendar
▸ Source: FMP · Metagenomi, Inc. Common Stock SEC filings · US GAAP · Metagenomi, Inc. Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026